Knowledge Assets

Useful Links

In the News

Partner Resources

Canadian Council of the Blind


  • Sharma, A., Kumar, N., Parachuri, N., Bandello, F., Kuppermann, B. D., and Loewenstein, A. (2021). Biosimilars for Retinal Diseases: An Update. American Journal of Ophthalmology, 224, 36-42.
  • Blake, M., & Caulfield, T. (2020). The Law and Ethics of Switching from Biologic to Biosimilar in Canada. Journal of the Canadian Association of Gastroenterology. DOI: 10.1093/jcag/gwz043
  • Sharma, A., et al. (2019). Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye.
  • Rezk, M. F., & Pieper, B. (2018). To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars. Advances in therapy, 35(6), 749–753.
  • Jacobs, I., Singh, E., Sewell, K. L., Al-Sabbagh, A., and Shane, L. G. (2016). Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Preference and Adherence, 10, pp. 937-948.